Buscar
18 estudios coinciden con estos filtros. Mostrando 1–18 de 18 estudios
| Número de registro | Estudio | Estado | Fase | Inscripción | Centros / países | Año de inicio | Última actualización | Acciones |
|---|---|---|---|---|---|---|---|---|
| NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine. ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 113 centros en total · contacto disponible | En reclutamiento | Fase 3 | 1800objetivo | 113 / 1 | 2026 | 2 nov 2026 | |
| NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 113 centros en total | En reclutamiento | Fase 3 | 1000objetivo | 113 / 1 | 2026 | 2 nov 2026 | |
| NCT06582810 | Lidocaine Infusion Treatment for Subarachnoid Hemorrhage Headaches The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to: 1. show that intravenous lidocaine infusion causes a clinically significa… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · contacto disponible | En reclutamiento | 20objetivo | 1 / 1 | 2025 | 10 jul 2026 | ||
| NCT05125302 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how sa… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 129 centros en total | En reclutamiento | Fase 3 | 1059objetivo | 129 / 2 | 2022 | 14 sept 2026 | |
| NCT06527222 | A Study of Ranolazine in ALS The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS. ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 6 centros en total · contacto disponible | En reclutamiento | Fase 2 | 72objetivo | 6 / 1 | 2025 | 18 nov 2026 | |
| NCT06847321 | Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P.… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 39 centros en total · contacto disponible | En reclutamiento | Fase 2 | 300objetivo | 39 / 1 | 2025 | 7 oct 2026 | |
| NCT06628908 | Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN). ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 76 centros en total | En reclutamiento | Fase 3 | 1100objetivo | 76 / 1 | 2024 | 15 oct 2026 | |
| NCT06990867 | Optimizing Reperfusion to Improve Outcomes and Neurologic Function The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 104 centros en total · contacto disponible | En reclutamiento | Fase 2 / Fase 3 | 740objetivo | 104 / 21 | 2025 | 21 sept 2026 | |
| NCT01574053 | Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 183 centros en total · contacto disponible | En reclutamientoNo verificado desde 1 feb 2024 | 35.000objetivo | 183 / 20 | 2012 | 28 feb 2024 | ||
| NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 117 centros en total · contacto disponible | En reclutamiento | Fase 3 | 770objetivo | 117 / 27 | 2026 | 22 sept 2026 | |
| NCT07609108 | Pridopidine Phase 3 Study in Huntington's Disease The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 66 centros en total · contacto disponible | En reclutamiento | Fase 3 | 400objetivo | 66 / 12 | 2026 | 19 nov 2026 | |
| NCT02523014 | Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g… ✓ Contacto✗ Reclamado Centro más cercano: Kingman, Kansas, United States — a 28 km · 791 centros en total | En reclutamiento | Fase 2 | 124objetivo | 791 / 1 | 2015 | 3 nov 2026 | |
| NCT05065216 | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limit… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 86 centros en total · contacto disponible | En reclutamiento | Fase 2 / Fase 3 | 728objetivo | 86 / 10 | 2021 | 14 sept 2026 | |
| NCT05561127 | Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures. ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 33 centros en total · contacto disponible | En reclutamiento | Fase 3 | 171objetivo | 33 / 1 | 2023 | 25 jun 2025 | |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 38 centros en total · contacto disponible | En reclutamiento | Fase 2 / Fase 3 | 71objetivo | 38 / 16 | 2022 | 15 jun 2026 | |
| NCT07190300 | TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) The purpose of this study is to evaluate the safety, tolerability, and efficacy of two different treatment combinations of tulmimetostat in participants with de novo or recurrent metastatic hormone-sensitive prostate cancer (mHSPC). Phase I aims to determine the recommended dose(s) for expansion (RD… ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 31 centros en total · contacto disponible | En reclutamiento | Fase 1 / Fase 2 | 181objetivo | 31 / 14 | 2026 | 13 nov 2026 | |
| NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel… ✓ Contacto✗ Reclamado Centro más cercano: El Dorado, Kansas, United States — a 85 km · 25 centros en total · contacto disponible | En reclutamiento | Fase 2 | 300objetivo | 25 / 1 | 2023 | 23 abr 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contacto✗ Reclamado Centro más cercano: Wichita, Kansas, United States — a 43 km · 279 centros en total · contacto disponible | En reclutamiento | 75.000objetivo | 279 / 6 | 2015 | 19 nov 2026 |